NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis

Cullinan Therapeutics, Inc. (CGEM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CGEM

$22.09

−$0.07 (−0.32%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CGEM with… →

CGEM Key Statistics

As of Sep 4, 2026
Trading
Open
$21.88
Previous Close
$22.16
Day's Range
21.77–22.30
52-Week Range
5.68–23.19
Volume
562.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.02
Valuation
Market Cap
$1.36B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.11
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$219.88M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.46M
1-Year Return
+219.68%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
892.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CGEM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+113.43%
2025−15.02%
2024+19.53%
2023−3.41%
2022−31.63%
2021−48.41%

As of September 4, 2026.

CGEM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$219.88M—
2024$0.00−$167.38M—
2023$0.00−$153.16M—
2022$0.00$111.21M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$241.65M−$219.88M—
2024$0.00—−$196.92M−$167.38M—
2023$0.00—−$190.65M−$153.16M—
2022$0.00—−$132.14M$111.21M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CGEM Valuation vs Biotechnology Median

Median of 656 stocks
MetricCGEMBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Cullinan Therapeutics, Inc. (CGEM) at $1.36B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 109 employees.

The most recent close on file for CGEM is $22.09, dated September 4, 2026. That is −$0.07 (−0.32%) against the previous close. Over the past 52 weeks the price has ranged from $5.68 to $23.19. The latest close sits 288.91% above that 52-week low.

Financial Health

In fiscal 2025, Cullinan Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $219.88M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −3.11.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +219.68%. Across 5 years the annualized return works out at −5.27%. Beta against the wider market is reported at 0.02. Annualized volatility over the trailing 5 years is 66.92%.

Growth & Income

No dividend is on file for CGEM.

Across the complete calendar years on file, 2024 returned +19.53% and 2021 returned −48.41%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the price is +113.43%.

Peer Comparison

Cullinan Therapeutics, Inc. (CGEM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cullinan Therapeutics, Inc. CGEM $1.36B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cullinan Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Visit website →